JAK2 and essential thrombocythemia: The identification of JAK2/MPL mutations has been essential for the diagnosis of myeloproliferative neoplasms, however, around 30–45% of ET and PMF remain wild-type for JAK2/MPL, and, in some this cases, diagnosis is difficult.